Comments on “Toxicity‐related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune‐based combinations ( ARON ‐1 study)”

Documenti analoghi

• Toxicity‐related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune‐based combinations ( ARON ‐1 study)
  di: Javier Molina‐Cerrillo, et al.
  Pubblicazione: (2025)
• Reply to: Comments on “Toxicity‐related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune‐based combinations ( ARON ‐1 study)”
  di: Javier Molina‐Cerrillo, et al.
  Pubblicazione: (2025)
• Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)
  di: Chiara Ciccarese, et al.
  Pubblicazione: (2024)
• Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
  di: Hao Xiong, et al.
  Pubblicazione: (2024)
• Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group
  di: Gökhan Şahin, et al.
  Pubblicazione: (2025)